思春期早発症治療の世界市場レポート 2024

思春期早発症治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.6%の年間複合成長率（CAGR）で23億米ドルに成長すると予想されます。予測期間中に予想される成長は、小児ヘルスケアインフラの拡大、個別化された治療アプローチの採用、心理社会的幸福への重点の集中、世界の保健への取り組み、患者と親向けの教育プログラムに起因すると考えられます。予測期間中に予想される主な動向には、ゴナドトロピン放出ホルモン（GnRH）アナログ製剤の進歩、新規治療ターゲットの探索、個別化治療アプローチ、長時間作用型製剤の統合、患者のコンプライアンスとアドヒアランスの重視、補助療法に関する進行中の研究、遠隔モニタリングのための遠隔医療の活用などがあります。

ホルモン疾患の有病率の増加により、思春期早発症治療市場の成長が促進されると予想されます。ホルモン障害には、ホルモンの生成と調節を担う内分泌系の機能不全や異常を伴う病状が含まれます。これらの疾患は、性ホルモンの正常な調節に障害があり、思春期の開始を制御する視床下部-下垂体-性腺（HPG）軸の早期活性化を引き起こす場合、思春期早発症を引き起こす可能性があります。たとえば、米国に拠点を置く医学図書館である国立医学図書館の2021年6月の報告書では、有病率は人口10万人あたり約45人、年間発生率は10万人あたり4件であることが示されています。したがって、ホルモン障害の有病率の増加は、思春期早発症治療市場の成長の重要な推進力です。

思春期早発症の発生率の増加が市場の成長に寄与すると予想されます。思春期早発症は、体の成人期などの変化が早すぎる子供の思春期の早期発症を特徴とする症状です。思春期早発症の治療は、ホルモンの不均衡を調整し、心理的健康をサポートし、成長パターンを正常化し、合併症を予防し、根本的な原因に対処することを目的としています。米国を拠点とする科学分野のオープンアクセスジャーナルの非営利出版社PLOSが共有した2023年3月の報告書では、中枢性思春期早発症（CPP）の年間発生率が大幅に増加していることが明らかになった。発生率は男子では10万人当たり1.2人から100人に83.3倍、女子では10万人当たり88.9人から1414.7人に15.9倍に上昇しました。少年少女の年間有病率は大幅に増加しており、思春期早発症の発生率の増加と市場での関連治療の需要の高まりを浮き彫りにしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の思春期早発症治療市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• リュープロレリン
• ヒストレリン
• トリプトレリン
• ナファレリン
• 世界の思春期早発症治療市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• クリニック
• その他の用途
• 世界の思春期早発症治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 小児患者
• 大人
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の思春期早発症治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の思春期早発症治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 思春期早発症治療市場の競合情勢
• 思春期早発症治療市場の企業プロファイル
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi SA
  • AstraZeneca plc
  • Abbott Laboratories

第31章 その他の主要および革新的な企業

• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd.
• Prime Therapeutics LLC
• Ipsen Ltd.
• Ferring Pharmaceuticals Private Limited
• Endo Pharmaceuticals Inc.
• Livzon Pharmaceutical Group Inc.
• Salvavidas Pharmaceutical Pvt. Ltd.
• Actiza Pharmaceutical Private Limited
• Biocon Limited
• Mallinckrodt plc
• Arbor Pharmaceuticals LLC
• Genentech Inc.
• Tolmar Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Precocious puberty treatment involves medical interventions and therapies designed to manage and address the early onset of puberty in children. The primary goal of treatment is to slow down or halt the progression of puberty, mitigate the impact on the child's growth potential, and address any underlying causes or associated health concerns.

The main drug classes utilized in precocious puberty treatment include leuprorelin, histrelin, triptorelin, and nafarelin. Leuprorelin, also known as leuprolide acetate, is a synthetic medication employed in the fields of reproductive medicine and endocrinology. It belongs to the class of drugs known as gonadotropin-releasing hormone (GnRH) agonists. These drugs find applications in various settings, including hospitals, clinics, and other healthcare facilities, and can be administered to pediatric patients, adults, and individuals in need of such treatments.

The precocious puberty treatment market research report is one of a series of new reports from The Business Research Company that provides precocious puberty treatment market statistics, including precocious puberty treatment industry global market size, regional shares, competitors with a precocious puberty treatment market share, detailed precocious puberty treatment market segments, market trends and opportunities, and any further data you may need to thrive in the precocious puberty treatment industry. This precocious puberty treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The precocious puberty treatment market size has grown strongly in recent years. It will grow from $1.57 billion in 2023 to $1.71 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historical period can be attributed to various factors, including the increased incidence of precocious puberty, a rise in awareness leading to early diagnosis, concerns expressed by patients and parents, collaborative efforts within the pediatric healthcare sector, and advocacy by pediatric endocrinologists.

The precocious puberty treatment market size is expected to see strong growth in the next few years. It will grow to $2.3 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to the expansion of pediatric healthcare infrastructure, the adoption of individualized treatment approaches, a heightened focus on psychosocial well-being, global health initiatives, and educational programs for patients and parents. Major trends expected in the forecast period include advancements in gonadotropin-releasing hormone (GnRH) analogues, exploration of novel therapeutic targets, personalized treatment approaches, the integration of long-acting formulations, emphasis on patient compliance and adherence, ongoing research on adjunct therapies, and the utilization of telemedicine for remote monitoring.

The increasing prevalence of hormonal disorders is expected to drive the growth of the precocious puberty treatment market. Hormonal disorders encompass medical conditions involving dysfunction or abnormalities in the endocrine system, responsible for producing and regulating hormones. These disorders can lead to precocious puberty when there is a disruption in the normal regulation of sex hormones, triggering the early activation of the hypothalamic-pituitary-gonadal (HPG) axis, which controls the onset of puberty. For instance, a June 2021 report from the National Library of Medicine, a U.S.-based medical library, indicated a prevalence of around 45 cases per 100,000 people, with a yearly incidence of 4 occurrences per 100,000 people. Therefore, the increasing prevalence of hormonal disorders is a key driver for the growth of the precocious puberty treatment market.

The rising incidence of precocious puberty cases is expected to contribute to the market's growth. Precocious puberty is a condition characterized by the premature onset of puberty in children, with their bodies undergoing adult-such as changes too early. Treatment for precocious puberty aims to regulate hormonal imbalances, support psychological well-being, normalize growth patterns, prevent complications, and address underlying causes. A March 2023 report shared by PLOS, a U.S.-based nonprofit publisher of open-access journals in science, revealed a significant increase in the annual incidence of central precocious puberty (CPP). The incidence rose by 83.3 times in boys, from 1.2 to 100 per 100,000, and 15.9 times in girls, from 88.9 to 1414.7 per 100,000. The annual prevalence in both boys and girls surged significantly, underscoring the growing incidence of precocious puberty cases and driving the demand for related treatments in the market.

The growth of the precocious puberty treatment market may face hindrances due to the impact of COVID-19 during the forecast period. Lockdowns and overwhelmed healthcare systems in specific regions may have disrupted regular healthcare services, including the monitoring and treatment of children with precocious puberty. For example, in July 2023, the National Library of Medicine reported that hospitals faced increased operating expenses for necessary supplies and rapidly escalating labor costs. Total hospital expenses increased by 4.5% from the same period the previous year, and during lockdowns, access to pediatric endocrinologists and necessary diagnostic tests might have been impeded, leading to delays in treatment initiation. Therefore, the impact of COVID-19 is acting as a hindrance to the growth of the precocious puberty treatment market.

Major companies in the precocious puberty treatment market are concentrating on obtaining drug approvals, such as leuprolide acetate injection, to drive organizational growth in the market. The increasing number of drug approvals for precocious puberty treatment, such as leuprolide acetate injection, provides new therapeutic options. For instance, in November 2022, Amneal Pharmaceuticals Inc., a U.S.-based pharmaceutical company, received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for leuprolide acetate injection. Leuprolide acetate is a synthetic form of gonadotropin-releasing hormone (GnRH) used to delay sexual development, such as the growth of breasts or testicles and the onset of menstruation.

In June 2022, Eversana Life Science Services LLC, a U.S.-based life sciences company, partnered with Accord BioPharma to support the launch of CAMCEVI for treating advanced prostate cancer in adults in the U.S. CAMCEVI (leuprolide mesylate) is also used to treat central precocious puberty. It is a synthetic hormone similar to a natural hormone produced in the brain, addressing various medical problems, including central precocious puberty. CAMCEVI is the first-ever sterile leuprolide ready-to-inject formulation for subcutaneous injection, delivered in a pre-filled syringe without the need for mixing. Accord BioPharma is a U.S.-based pharmaceutical company focused on developing and marketing treatments for various conditions, including central precocious puberty.

Major companies operating in the precocious puberty treatment market report are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Prime Therapeutics LLC, Ipsen Ltd., Ferring Pharmaceuticals Private Limited, Endo Pharmaceuticals Inc., Livzon Pharmaceutical Group Inc., Salvavidas Pharmaceutical Pvt. Ltd., Actiza Pharmaceutical Private Limited, Biocon Limited, Mallinckrodt PLC, Arbor Pharmaceuticals LLC, Genentech Inc., Tolmar Pharmaceuticals Inc., Debiopharm Group, Emcure Pharmaceuticals Ltd., Cadila Pharmaceuticals Limited, Sandoz International GmbH, Banner Life Sciences LLC, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc.

North America was the largest region in the precocious puberty treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precocious puberty treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the Precocious Puberty Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The precocious puberty treatment market consists of revenues earned by entities by providing services such as medical evaluation, hormone therapy, monitoring and follow-up, psychological and emotional support, nutritional guidance, parent and caregiver education, and social and school support. The market value includes the value of related goods sold by the service provider or included within the service offering. The precocious puberty treatment market also includes sales of gonadotropin hormone-releasing hormone (GnRH), triptorelin, and leuprolide acetate. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Precocious Puberty Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on precocious puberty treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for precocious puberty treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The precocious puberty treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Leuprorelin; Histrelin; Triptorelin; Nafarelin
• 2) By Application: Hospitals; Clinics; Other Applications
• 3) By End-User: Pediatric Patients; Adults; Other End-Users
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; AstraZeneca plc; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Precocious Puberty Treatment Market Characteristics

3. Precocious Puberty Treatment Market Trends And Strategies

4. Precocious Puberty Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Precocious Puberty Treatment Market Size and Growth

• 5.1. Global Precocious Puberty Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Precocious Puberty Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Precocious Puberty Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Precocious Puberty Treatment Market Segmentation

• 6.1. Global Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Leuprorelin
• Histrelin
• Triptorelin
• Nafarelin
• 6.2. Global Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Other Applications
• 6.3. Global Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Pediatric Patients
• Adults
• Other End-Users

7. Precocious Puberty Treatment Market Regional And Country Analysis

• 7.1. Global Precocious Puberty Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Precocious Puberty Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Precocious Puberty Treatment Market

• 8.1. Asia-Pacific Precocious Puberty Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Precocious Puberty Treatment Market

• 9.1. China Precocious Puberty Treatment Market Overview
• 9.2. China Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Precocious Puberty Treatment Market

• 10.1. India Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Precocious Puberty Treatment Market

• 11.1. Japan Precocious Puberty Treatment Market Overview
• 11.2. Japan Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Precocious Puberty Treatment Market

• 12.1. Australia Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Precocious Puberty Treatment Market

• 13.1. Indonesia Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Precocious Puberty Treatment Market

• 14.1. South Korea Precocious Puberty Treatment Market Overview
• 14.2. South Korea Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Precocious Puberty Treatment Market

• 15.1. Western Europe Precocious Puberty Treatment Market Overview
• 15.2. Western Europe Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Precocious Puberty Treatment Market

• 16.1. UK Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Precocious Puberty Treatment Market

• 17.1. Germany Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Precocious Puberty Treatment Market

• 18.1. France Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Precocious Puberty Treatment Market

• 19.1. Italy Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Precocious Puberty Treatment Market

• 20.1. Spain Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Precocious Puberty Treatment Market

• 21.1. Eastern Europe Precocious Puberty Treatment Market Overview
• 21.2. Eastern Europe Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Precocious Puberty Treatment Market

• 22.1. Russia Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Precocious Puberty Treatment Market

• 23.1. North America Precocious Puberty Treatment Market Overview
• 23.2. North America Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Precocious Puberty Treatment Market

• 24.1. USA Precocious Puberty Treatment Market Overview
• 24.2. USA Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Precocious Puberty Treatment Market

• 25.1. Canada Precocious Puberty Treatment Market Overview
• 25.2. Canada Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Precocious Puberty Treatment Market

• 26.1. South America Precocious Puberty Treatment Market Overview
• 26.2. South America Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Precocious Puberty Treatment Market

• 27.1. Brazil Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Precocious Puberty Treatment Market

• 28.1. Middle East Precocious Puberty Treatment Market Overview
• 28.2. Middle East Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Precocious Puberty Treatment Market

• 29.1. Africa Precocious Puberty Treatment Market Overview
• 29.2. Africa Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Precocious Puberty Treatment Market Competitive Landscape And Company Profiles

• 30.1. Precocious Puberty Treatment Market Competitive Landscape
• 30.2. Precocious Puberty Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. AbbVie Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Sanofi S.A.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AstraZeneca plc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Abbott Laboratories
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Precocious Puberty Treatment Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Glenmark Pharmaceuticals Ltd.
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Prime Therapeutics LLC
• 31.5. Ipsen Ltd.
• 31.6. Ferring Pharmaceuticals Private Limited
• 31.7. Endo Pharmaceuticals Inc.
• 31.8. Livzon Pharmaceutical Group Inc.
• 31.9. Salvavidas Pharmaceutical Pvt. Ltd.
• 31.10. Actiza Pharmaceutical Private Limited
• 31.11. Biocon Limited
• 31.12. Mallinckrodt plc
• 31.13. Arbor Pharmaceuticals LLC
• 31.14. Genentech Inc.
• 31.15. Tolmar Pharmaceuticals Inc.

32. Global Precocious Puberty Treatment Market Competitive Benchmarking

33. Global Precocious Puberty Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Precocious Puberty Treatment Market

35. Precocious Puberty Treatment Market Future Outlook and Potential Analysis

• 35.1 Precocious Puberty Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Precocious Puberty Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Precocious Puberty Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer